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Abstract: Despite the increasing availability of new classes of cancer treatment, such as immune-
and targeted therapies, there remains a need for the development of new antiproliferative/cytotoxic
drugs with improved pharmacological profiles that can also overcome drug resistant forms of cancer.
In this study, we have identified, and characterised, a novel marine polysaccharide with the potential
to be developed as an anticancer agent. Sulphated polysaccharides isolated from the common cockle
(Cerastoderma edule) were shown to have antiproliferative activity on chronic myelogenous leukaemia
and relapsed acute lymphoblastic leukaemia cell lines. Disaccharide and monosaccharide analysis of
these marine polysaccharides confirmed the presence of glycosaminoglycan-like structures that were
enriched in ion-exchange purified fractions containing antiproliferative activity. The antiproliferative
activity of these glycosaminoglycan-like marine polysaccharides was shown to be susceptible to
heparinase but not chondrotinase ABC digestion. This pattern of enzymatic and antiproliferative
activity has not previously been seen, with either marine or mammalian glycosaminoglycans. As such,
our findings suggest we have identified a new type of marine derived heparan sulphate/heparin-like
polysaccharide with potent anticancer properties.
Keywords: marine mollusc; glycosaminoglycans; antiproliferative; anticancer; heparan sulphate
1. Introduction
Glycosaminoglycans (GAGs) are a complex family of polysaccharides found in both vertebrates
and invertebrates. They bind to many proteins and mediate a diverse range of biological functions,
including both cellular and physiological events [1]. These molecules are widely exploited as
therapeutics, for example, hyaluronic acid (HA) and chondroitin sulphate (CS) are used to treat
osteoarthritis, and of course heparin has been used as an anticoagulant and antithrombotic drug
for more than 70 years [2]. However, no native mammalian GAGs have been shown to have direct
cytotoxic or antiproliferative effects on cancer cells. There are five families of mammalian GAGs,
each based on their repeating disaccharide units. These are heparan sulphate (HS) including the
related molecule heparin, CS, dermatan sulphate (DS), keratan sulphate and the unsulphated HA.
Heparan sulphate and CS/DS GAG chains are initially synthesised as an alternating backbone of
N-acetylated amino sugar, either N-acetylglucosamine (GlcNAc) in HS or N-acetylgalactosamine
(GalNAc) in CS/DS and glucuronic acid (GlcA), or its C5 epimer iduronic acid (IdoA). Epimerisation
takes place to differing extents in HS and heparin and in the conversion of CS into DS. Further
modifications occur by N-sulphation of the amino sugar (GlcNS) in HS/heparin and O-sulphation
at various positions on the sugar units, commonly 2-O- and 6-O-positions [3]. The extent of both
epimerisation and sulphation defines the interactions that take place between GAGs and their protein
receptor partners [4]. Mammalian GAGs, in particular HS, are very heterogeneous in structure and
are organised into subdomains that contain regions of high sulphation [5], which are important for
interactions with proteins [6].
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Marine invertebrates are a rich source of potential therapeutics and marine carbohydrates have
been shown to have complex structures and biological activities [7]. Marine polysaccharides differ
considerably from their mammalian counterparts, in terms of their structure and biological activities.
As a result, they provide important new opportunities as carbohydrate based therapeutics [8].
The principle marine glycans are comprised of non-sulphated chitin, chitosan, sulphated GAGs,
sulphated fucans and sulphated galactans. Marine polysaccharides from seaweed and algae have
been shown to have anticancer activities but these are largely related to polysulphated fucans that are
not directly members of the GAG family [8]. Sulphated fucans or fucoidans from marine sources are
comprised of homogeneous unbranched polymers of (1–3) or (1–4) linked L-fucose units, which can
be substituted with sulphate groups at positions C-2, C-4 and rarely at C-3. They may also be
heterogeneous branched polymers with variable content of uronic acids and neutral sugars [9].
Single fucose units, or short fuco-oligosaccharide branches, can also be present on the polysaccharide
backbone, usually at the C-4 position. Structural features within Fucoidans have been linked to many
beneficial effects including anticancer [10–12], antiviral [13], anti-inflammatory [14] and antithrombotic
activities [15]. GAG-like polysaccharides have been isolated from many marine species, including
molluscs and in some instances, HS structures were found to be similar to heparin. Marine DS and CS
have backbone structures comparable to mammalian GAGs but with differing sulphation patterns.
Fucosylated CS and CS/DS hybrid chains have also been identified from marine sources [16,17].
Marine GAGs have not previously been linked with antiproliferative or cytotoxic effects on cancer cells.
In this study, we have shown that marine derived GAG-like polysaccharides from the
common cockle (Cerastoderma edule) have antiproliferative activity on two cancer cell lines.
Enzyme depolymerisation and structural analysis suggest that novel HS-like structures are responsible
for the antiproliferative activity of the marine derived polysaccharides.
2. Results
2.1. Polysaccharide Isolation and Anticancer Activity
Numerous studies have portrayed the potential medicinal properties of marine polysaccharides,
mainly from seaweed, and some have even demonstrated cytotoxic effects using both in vitro and
in vivo models [18]. In this study, we show for the first time that marine polysaccharides isolated from
molluscs, with structural similarities to mammalian GAGs, have in vitro antiproliferative effects on
cancer cell lines.
Marine polysaccharides were isolated from common cockles, following a typical cetylpyridinium
chloride extraction procedure [19]. The cockle polysaccharides were assessed against two leukaemia
cell lines (K562 and MOLT4) for their ability to suppress cancer cell growth. The cockle polysaccharides
showed considerable inhibition of cell proliferation with these cell lines, as determined by
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Figure 1).
Some batch-to-batch variability in IC50 values was seen with different isolations of cockle
polysaccharides, presumably because of the complex heterogeneous mixture of polysaccharide chains
present. Cisplatin was used in all assays, as a control for comparison of different preparations.
Typical IC50 values were around 9 µg/mL and 1 µg/mL, respectively, for cell lines K562 and MOLT4.
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Figure 1. Antiproliferative activity of cockle polysaccharides on cancer cell lines. Two cancer cell lines 
K562  (A)  and MOLT4  (B) were  treated with  increasing  doses  of  cockle polysaccharides  and  cell 
viability was determined by MTT assay, as detailed in the “Materials and Methods” section. Inserts 
show  effects  of  cisplatin  treatment  on  viable  cell  number.  Cells  were  cultured  under  standard 
conditions and maintained at 37 °C in a humidified 5% CO2 atmosphere. Cell viability is expressed as 
a percentage relative to untreated control cells. All experiments were conducted in triplicate and the 
IC50 values were calculated using non‐linear regression analysis (GraphPad Prism 5.0). 
2.2. Annexin V Apoptosis Detection and Cell Cycle Analysis 
Cell Cycle analysis of MOLT‐4 cells (Figure 2A,C) showed an increase in cell numbers in both 
G1 and G2/M phases after 24 h exposure to cockle polysaccharides, accompanied by a lowering of 
cells in S‐phase. These data, and the presence of cells in sub G1, indicate a complex mechanism of cell 
death,  following  treatment of MOLT‐4 cells with cockle polysaccharides, potentially mediated via 
apoptosis.  Flow  cytometry  and Annexin V/ propidium  iodide  (PI)  staining, was used  to  further 
investigate  the mechanism of cell death  following cockle polysaccharide  treatment  (Figure 2B,D). 
Leukaemia cell line MOLT‐4 showed small but significant increases in late apoptotic (Annexin V+/PI+) 
cells when treated with cockle polysaccharide, However, early apoptotic (Annexin V+/PI−) showed 
the biggest change in cell populations after a 24 h incubation. Necrotic (Annexin V−/PI+) cells showed 
little change over untreated controls. The results shown in Figure 2 clearly implicate apoptosis as the 
most likely cause of the cytotoxicity seen following treatment by cockle polysaccharides. However, 
primary necrosis  cannot be  ruled out. Data  from K562  cells were not obtained, as  their  inherent 
tendency to aggregate proved problematic in the flow cytometry studies. 
2.3. Effect of Enzymatic Degradation on Cockle Polysaccharide Anticancer Activities 
The extraction procedure used, whilst designed to enrich the content of sulphated GAG or GAG‐
like structures, will also bring contamination from other marine polysaccharides. These non‐GAG 
polysaccharides may contribute  solely, or  in part,  to  the observed antiproliferative activity of  the 
cockle polysaccharides. Enzymatic treatment of the cockle polysaccharides by heparinases I, II, III 
and chondroitinase ABC was used to investigate any link between typical GAG‐like structures and 
the observed antiproliferative activity. Figure 3 demonstrates that there is no appreciable change in 
antiproliferative  activity  when  cockle  polysaccharides  are  incubated  with  chondroitinase  ABC. 
Heparinase treatment (individually and  in combination) however, did  lead to a significant  loss of 
biological activity, with an approximate increase in IC50 values for combined heparinases I, II, III of 
around 4‐ and 8‐fold for K562 and MOLT4 cell lines respectively. There was little difference between 
the  individual  heparinases  enzymes,  however  in  replicates  heparinase  II, was  consistently more 
effective at reducing the antiproliferative effects of the cockle polysaccharides. Despite the significant 
loss in activity, inhibition was not entirely destroyed by heparinase treatment, even when used in 
combination. This suggest  that a proportion of  resistant disaccharide  linkages may exist and  that 
resistant fragments are of sufficient size to still function as an antiproliferative. Taken together, the 
data suggest that HS/heparin like GAG structures are key contributors to the antiproliferative activity 
of the cockle polysaccharides, with CS‐like GAGs contributing little to the anticancer affect. 
Figure 1. Antiproliferative activity of cockle polysaccharides on cancer cell lines. Two cancer cell lines
K562 (A) and MOLT4 (B) were treated with increasing doses of cockle polysaccharides and cell viability
was determined by MTT assay, as detailed in the “Materials and Methods” section. Inserts show
effects of cisplatin treatment on viable cell number. Cells were cultured under standard conditions and
maintained at 37 ◦C in a humidified 5% CO2 atmosphere. Cell viability is expressed as a percentage
relative to untreated control cells. All experiments were conducted in triplicate and the IC50 values
were calculated using non-linear regression analysis (GraphPad Prism 5.0).
2.2. Annexin V Apoptosis Detection and Cell Cycle Analysis
Cell Cycle analysis of MOLT-4 cells (Figure 2A,C) showed an increase in cell numbers in both G1
and G2/M phases after 24 h exposure to cockle polysaccharides, accompanied by a lowering of cells in
S-phase. These data, and the presence of cells in sub G1, indicate a complex mechanism of cell death,
following treatment of MOLT-4 cells with cockle polysaccharides, potentially mediated via apoptosis.
Flow cytometry and Annexin V/propidium iodide (PI) staining, was used to further investigate the
mechanism of cell death following cockle polysaccharide treatment (Figure 2B,D). Leukaemia cell line
MOLT-4 showed small but significant increases in late apoptotic (Annexin V+/PI+) cells when treated
with cockle polysaccharide, However, early apoptotic (Annexin V+/PI−) showed the biggest change
in cell populations after a 24 h incubation. Necrotic (Annexin V−/PI+) cells showed little change over
untreated controls. The results shown in Figure 2 clearly implicate apoptosis as the most likely cause
of the cytotoxicity seen following treatment by cockle polysaccharides. However, primary necrosis
cannot be ruled out. Data from K562 cells were not obtained, as their inherent tendency to aggregate
proved problematic in the flow cytometry studies.
2.3. Effect of Enzymatic Degradation on Cockle Polysaccharide Anticancer Activities
The extraction procedure used, whilst designed to enrich the content of sulphated GAG or
GAG-like structures, will also bring contamination from other marine polysaccharides. These non-GAG
polysaccharides may contribute solely, or in part, to the observed antiproliferative activity of the
cockle polysaccharides. Enzymatic treatment of the cockle polysaccharides by heparinases I, II,
III and chondroitinase ABC was used to investigate any link between typical GAG-like structures
and the observed antiproliferative activity. Figure 3 demonstrates that there is no appreciable change
in antiproliferative activity when cockle polysaccharides are incubated with chondroitinase ABC.
Heparinase treatment (individually and in combination) however, did lead to a significant loss of
biological activity, with an approximate increase in IC50 values for combined heparinases I, II, III of
around 4- and 8-fold for K562 and MOLT4 cell lines respectively. There was little difference between the
individual heparinases enzymes, however in replicates heparinase II, was consistently more effective
at reducing the antiproliferative effects of the cockle polysaccharides. Despite the significant loss in
activity, inhibition was not entirely destroyed by heparinase treatment, even when used in combination.
This suggest that a proportion of resistant disaccharide linkages may exist and that resistant fragments
are of sufficient size to still function as an antiproliferative. Taken together, the data suggest that
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Figure 2. Cell cycle analysis and Annexin V apoptosis assay. MOLT4 cells were treated with 50 μg of 
cockle polysaccharides for 24 h then stained using Annexin V conjugated Fluorescein isothiocyanate 
(Annexin V‐FITC) and/or PI. (A) Flow cytometry cell cycle analysis of PI stained cells with or without 
cockle polysaccharide treatment. A single representative experiment  is shown. (B) Flow cytometry 
scatter plot of Annexin V‐FITC/PI stained cells with or without cockle polysaccharide treatment. A 
single representative experiment is shown. (C) Quantitative cell cycle analysis as determined by PI 
staining and flow cytometry. The percentage of cells in each phase is shown for control () and cockle 
polysaccharide  treated  ()  cells.  Results  are  presented  as  the mean  ±  SD  of  three  independent 
experiments. Statistical significance was determined using the two‐tailed Student’s t‐test. p < 0.05 was 
considered  statistically  significant  (*).  (D)  Quantitative  analysis  of  apoptosis  as  determined  by 
Annexin V‐FITC/PI staining and flow cytometry. The percentage of cells in each quadrant is shown 
for control () and cockle polysaccharide treated () cells. Results are presented as the mean ± SD of 
three independent experiments. Statistical significance was determined using the two‐tailed Student’s 
t‐test. p < 0.05 was considered statistically significant (*). 
2.4. Comparisons of Marine GAG Antiproliferative Activity with Mammalian GAGs 
The potent antiproliferative effect of cockle polysaccharides was surprising, as the anticancer 
activity appeared to be linked to the presence of mammalian HS/heparin‐like structures, which to 
our knowledge have never shown direct antiproliferative effects on cancer cell lines in vitro. Further 
investigation confirmed that mammalian derived GAGs (porcine mucosal) had no antiproliferative 
activity in our MTT assay system. Figure 4 shows that no measurable IC50 could be determined for 
mammalian HS, with  either  cancer  cell  line,  yet  the  cockle  polysaccharides  continued  to  show 
significant  antiproliferative  activity.  In  fact,  at  low  concentrations mammalian HS  showed  slight 
stimulatory activity on cell growth. The results suggest that, if HS‐like‐GAG chains are involved in 
the  antiproliferative  activity  of  cockle polysaccharides,  then  they must  contain unique  structural 
features not found in typical mammalian GAGs. 
Figure 2. Cell cycle analysis and Annexin V apoptosis assay. MOLT4 cells were treated with 50 µg of
cockle polysaccharides for 24 h then stained using Annexin V conjugated Fluorescein isothiocyanate
(Annexin V-FITC) and/or PI. (A) Flow cytometry cell cycle analysis of PI stained cells with or without
cockle polysaccharide treatment. A single representative experiment is shown. (B) Flow cytometry
scatter plot of Annexin V-FITC/PI stained cells with or without cockle polysaccharide treatment.
A single representative experiment is shown. (C) Quantitative cell cycle analysis as determined by
PI staining and flow cytometry. The percentage of cells in each phase is shown for control () and
cockle polysaccharide treated () cells. Results are presented as the mean ± SD of three independent
experiments. Statistical significance was determined using the two-tailed Student’s t-test. p < 0.05
was considered statistically significant (*). (D) Quantitative analysis of apoptosis as determined by
Annexin V-FITC/PI staining and flow cytometry. The percentage of cells in each quadrant is shown
for control () and cockle polysaccharide treated () cells. Results are presented as the mean ± SD of
three independent experiments. Statistical significance was determined using the two-tailed Student’s
t-test. p < 0.05 was considered statistically significant (*).
2.4. Comparisons of Marine GAG Antiproliferative Activity with Mammalian GAGs
The pote t antip oliferative effect of cockle polysacc arides was surprising, as the anticancer
activity appeared to be linked to the presence of mammalian HS/heparin-like structures, which to
our knowledge have never shown direct antiproliferative effects on cancer cell lines in vitro. Further
investigation confirmed that mammalian derived GAGs (porcine mucosal) had no antiproliferative
activity in our MTT assay system. Figure 4 shows that no measurable IC50 could be determined
for mammalian HS, with either cancer cell line, yet the cockle polysaccharides continued to show
significant antiproliferative activity. In fact, at low concentrations mammalian HS showed slight
stimulatory activity on cell growth. The results suggest that, if HS-like-GAG chains are involved in the
antiproliferative activity of cockle polysaccharides, then they must contain unique structural features
not found in typical mammalian GAGs.
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Figure 3. Effect of heparinase (I, II, and III) and chondroitinase ABC enzymatic degradation on cockle 
polysaccharide  antiproliferative  activity.  Sensitivity  of  the  cockle  polysaccharide  antiproliferative 
activity to enzymatic degradation was determined by MTT assay. Antiproliferative activity of cockle 
polysaccharides on K562 cells (A) and MOLT4 cells (B), with and without heparinase or chondrotinase 
ABC digestion. Intact cockle polysaccharides (), heparinase I treated (∆), heparinase II treated (▲), 
heparinase III treated (), heparinase I, II, and III treated () and chondroitinase ABC (). The data 
are  presented  as  the  percentage  of  viable  cells  following  treatment with  cockle  polysaccharides, 
relative to untreated control. All experiments were conducted in triplicate and the results are shown 
as the mean ± the SD. Cells were cultured in suspension and maintained at 37 °C in humidified 5% 
CO2 atmosphere. 
 
Figure  4. Comparison of mammalian GAGs  and  cockle polysaccharides  antiproliferative  activity. 
Differences in biological activities of mammalian GAGs and cockle polysaccharides on K562 (A) and 
MOLT4 (B) cell lines was assessed by MTT assay, cockle polysaccharides (), mammalian HS (). 
Data are presented as the percentage of viable cells following treatment with cockle polysaccharides, 
relative to untreated control. All experiments were conducted in triplicate and the results are shown 
as the mean ± the SD. Cells were cultured in suspension and maintained at 37 °C in humidified 5% 
CO2 atmosphere. 
2.5. Disaccharide Analysis of GAGs 
Disaccharide analysis was used solely to confirm the presence of typical unsaturated HS and 
CS/DS disaccharides, following treatment of the cockle polysaccharides with heparinase I, II and III 
or chondroitinase ABC and was not part of any detailed structure/activity study. 
Initial analysis of the HS/heparin disaccharide compositions, produced by combined heparinase 
I, II, III digestion, showed that susceptible chains within the cockle polysaccharide preparations did 
contain the major disaccharide species found in mammalian HS and heparin. Care must be taken in 
attributing total HS disaccharide compositions to these chains, as activity data (Figure 3) suggest that 
the combined heparinase I, II, and III digests are possibly incomplete. The major differences between 
disaccharides derived from heparinase digestion of mammalian HS and the cockle polysaccharide 
(Table 1) were the low levels of unsulphated disaccharide ∆HexA‐GlcNAc and the high levels of the 
disulphated  disaccharide  ∆HexA‐GlcNS(6S)  released  from  the  cockle  polysaccharides.  Other 
disaccharides were obtained at similar levels to those seen with many typical mammalian HS types. 
Figure 3. Effect of heparinase (I, II, and III) and chondroitinase ABC enzymatic degradation on cockle
polysaccharide antiproliferative activity. Sensitivity of the cockle polysaccharide antiproliferative activity to
enzymatic degradation was determined by MTT assay. Antiproliferative activity of cockle polysaccharides
on K562 cells (A) and MOLT4 cells (B), with and without heparinase or chondrotinase ABC digestion.
Intact cockle polysaccharides (#), heparinase I treated (∆), heparinase II treated (N), heparinase III treated
(), heparinase I, II, and III treated () and chondroitinase ABC ( ). The data are presented as the
percentage of viable cells following treatment with cockle polysaccharides, relative to untreated control.
All experiments were conducted in triplicate and the results are shown as the mean ± the SD. Cells were
cultured in suspension and maintained at 37 ◦C in humidified 5% CO2 atmosphere.
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Figure  4. Comparison of mammalian GAGs  and  cockle polysaccharides  antiproliferative  activity. 
Differences in biological activities of mammalian GAGs and cockle polysaccharides on K562 (A) and 
MOLT4 (B) cell lines was assessed by MTT assay, cockle polysaccharides (), mammalian HS (). 
Data are presented as the percentage of viable cells following treatment with cockle polysaccharides, 
relative to untreated control. All experiments were conducted in triplicate and the results are shown 
as the mean ± the SD. Cells were cultured in suspension and maintained at 37 °C in humidified 5% 
CO2 atmosphere. 
2.5. Disaccharide Analysis of GAGs 
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and the high levels of the disulphated disaccharide ∆HexA-GlcNS(6S) released from the cockle
polysaccharides. Other disaccharides were obtained at similar levels to those seen with many
typical mammalian HS types. The heparinases failed to generate high quantities of the trisulphated
disaccharide ∆HexA(2S)-GlcNS(6S) from the crude cockle polysaccharides, indicating that the HS-like
cockle polysaccharides chains are more akin to mammalian HS than heparin. CS/DS disaccharide
analysis was carried out, despite the fact that chondrotinase ABC treatment of cockle polysaccharides
failed to show any significant loss of antiproliferative activity. The principle disaccharide components
produced by chondroitinase ABC digestion were ∆HexA-GalNAc(4S), ∆HexA-GalNAc(6S) and
∆HexA-GalNAc(4S)(6S). The results clearly show that CS/DS-like chains are also present in the
cockle polysaccharide preparations.
Disaccharide analysis data support the initial suggestion that the reduction in antiproliferative
activity, following treatment of cockle polysaccharides with heparinases, was due to their breakdown.
Resulting in the release of unsaturated disaccharides commonly found in mammalian HS/heparin.
The lack of activity seen with the mammalian GAGs in the MTT assay, and the presence of heparinase
resistant fragments within the cockle polysaccharides, suggests that the active HS-like-chains differ
considerably from their mammalian counterparts.
Table 1. Disaccharide analysis of crude unfractionated cockle polysaccharides. 1: Data are presented as
a percentage of the moles of CS/DS and HS unsaturated disaccharides produced by chondroitinase
ABC and heparinase I, II, and III digestion.
HS Disaccharides Disaccharides Produced (%) 1
∆HexA-GlcNAc 26.6
∆HexA(2S)-GlcNAc 0.0
∆HexA(2S)-GlcNH2 0.0
∆HexA-GlcNAc(6S) 4.1
∆HexA(2S)-GlcNAc(6S) 4.0
∆HexA-GlcNS 25.5
∆HexA(2S)-GlcNS 9.5
∆HexA-GlcNS(6S) 24.7
∆HexA-GlcNH2(6S) 0.0
∆HexA(2S)-GlcNS(6S) 5.6
∆HexA(2S)-GlcNH2(6S) 0.0
CS/DS Disaccharides Disaccharides Produced (%) 1
∆HexA-GalNAc 3.2
∆HexA-GalNAc(4S) 33.5
∆HexA-GalNAc(6S) 17.2
∆HexA(2S)-GalNAc(4S) 0.0
∆HexA(2S)-GalNAc(6S) 0.7
∆HexA-GalNAc(4S)(6S) 45.4
∆HexA(2S)-GalNAc(4S)(6S) 0.0
Abbreviations: ∆HexA, 4,5 unsaturated uronic acid; GlcNAc, N-acetylglucosamine; GlcNS, N-sulphated
glucosamine; GlcNH2, glucosamine; GalNAc, N-acetylgalactosamine; 2S, 2-O-sulphate; 4S, 4-O-sulphate; 6S,
6-O-sulphate.
2.6. Ion-Exchange Chromatography
The complexity of the cockle polysaccharide mixtures limited our ability to identity particular
structural features responsible for their antiproliferative effects. Clearly, the cockle polysaccharides
contain both HS and CS/DS-like chains and probably other non-GAG chains. Consequently,
ion-exchange chromatography was performed to evaluate further the structure/activity features of the
components contained within the unfractionated cockle polysaccharides preparations. The elutant
was monitored at 280 nM to detect the peptide fragments still attached to the polysaccharide chains
following the initial protease digestion. A typical elution profile is shown in Figure 5, with six peaks
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generally occurring. The absorbance measured under each peak was broadly comparable to the dry
weights of polysaccharides obtained after desalting and lyophilisation.Mar. Drugs 2018, 16, x    7 of 16 
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Figure 6. Antiproliferative properties of the i - e rified cockle polysaccharide fractions.
Measurement of antiproliferative activi y of ion-exchanged purified fractions K562 (A) and MOLT4
(B) cells was achieved by MTT assay. Fraction 1 (#), Fraction 2 (), Fraction 3 (∆), Fraction 4, (),
Fraction 5 (N) a d Fraction 6 ( ). The data are presented as the percentage of viable cells following
treatme t with cockle polys ccharid , relative t u treated control. All experiments were conducted
in triplicate and the results are shown as the mean ± the SD. Cells were cultured in suspension and
maintained at 37 ◦C in humidified 5% CO2 atmosphere.
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2.8. Disaccharide Analysis of Ion-Exchange Purified Polysaccharides
Disaccharide analysis of the ion-exchange purified fractions was used to identify further the
nature of the different glycan chain types within the cockle polysaccharide preparations and to
confirm the role of HS-like-GAG structures in the antiproliferative activity. Table 2 shows the
relative distribution of unsaturated disaccharides and the amounts produced when each fraction was
treated exhaustively with a combination of heparinases I, II and III. The total weight of disaccharides
produced from each microgram of sample digested showed that only Fraction 5 produced a significant
amount of unsaturated disaccharides. Fractions 2, 3, 4 and 6 produced approximately 30-, 150-, 30-,
6- and 5-fold less disaccharide than Fraction 5, respectively, suggesting that the early eluting fraction
contain mainly non HS-like chains. The composition of Fractions 5 and 6 showed the presence of
all the major disaccharides found in mammalian HS/heparin. The enrichment of the trisulphated
disaccharide ∆HexA(2S)-GlcNS(6S) and the disulphated disaccharides ∆HexA(2S)-GlcNS with an
approximate four-fold and three-fold increase, respectively, in comparison to the unfractionated cockle
polysaccharides (Table 1), likely contributes significantly to the later elution of these chains from the
ion-exchange column. Fraction 1 appears to generate a higher proportion of sulphated disaccharides
than any other fraction; however, the quantity, in µg, of disaccharides produced is very small in
comparison to the total material digested. In fact, there is little correlation between the increase in the
number of sulphates per disaccharide produced from heparinase digestion and the elution position of
Fractions 1–4. This is likely linked to the limited digestion of the glycan chains contained within them.
Table 2. HS Disaccharide analysis of ion-exchange purified cockle polysaccharide fractions. Data are
presented as a percentage of the moles of unsaturated disaccharides produced by heparinase I, II,
III digestion of the ion-exchange fractions (F1–F6).
HS Disaccharides F1 (%) F2 (%) F3 (%) F4 (%) F5 (%) F6 (%)
∆HexA-GlcNAc 4.6 28.0 84.4 31.9 9.8 6.8
∆HexA(2S)-GlcNAc 0.0 0.0 0.0 0.0 0.9 0.4
∆HexA(2S)-GlcNH2 0.0 0.0 0.0 0.1 0.2 0.0
∆HexA-GlcNAc(6S) 0.2 2.4 1.6 5.3 4.9 3.3
∆HexA(2S)-GlcNAc(6S) 30.4 10.9 0.0 0.0 3.1 4.6
∆HexA-GlcNS 0.7 8.6 12.9 28.4 10.4 5.9
∆HexA(2S)-GlcNS 16.6 25.2 0.5 12.8 24.4 34.0
∆HexA-GlcNS(6S) 4.9 10.9 0.6 15.9 19.4 16.4
∆HexA-GlcNH2(6S) 0.0 0.0 0.0 0.1 0.2 0.0
∆HexA(2S)-GlcNS(6S) 42.7 14.0 0.0 5.7 26.3 28.6
∆HexA(2S)-GlcNH2(6S) 0.0 0.0 0.0 0.0 0.3 0.1
Unsulphated 4.6 28.0 84.4 31.9 9.8 6.8
N-SO3 64.8 58.8 14.0 62.6 80.5 84.8
2-O-SO3 89.6 50.2 0.6 18.5 55.3 67.6
6-O-SO3 78.1 38.2 2.2 27.0 54.2 53.0
Total GAG disaccharides produced
by heparinase digestion (µg) 0.01 0.002 0.01 0.05 0.29 0.06
Average sulphate per disaccharide 2.33 1.47 0.17 1.08 1.9 2.05
Abbreviations: ∆HexA, 4,5 unsaturated uronic acid; GlcNAc, N-acetylglucosamine; GlcNS, N-sulphated
glucosamine; GlcNH2, glucosamine; GalNAc, 2S, 2-O-sulphate; 6S, 6-O-sulphate
Disaccharide analysis of each fraction, following chondroitinase ABC digestion (Table 3),
also showed early eluting fractions lacked correlation between the sulphate content of the resultant
disaccharides and the fractions elution position. Again, this is likely linked to the incomplete nature
of the digests, as confirmed by the quantity, in µg, of disaccharides released by digestion. The later
eluting fractions produced disaccharides compositions close to those seen for the unfractionated cockle
polysaccharides (Table 1). The later eluting Fractions 5 and 6 contain CS-like-GAG chains, however
Figure 3 suggests that these chains do not contribute to the antiproliferative activity of Fraction 5.
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Table 3. CS/DS Disaccharide analysis of ion-exchange purified cockle polysaccharide fractions.
Data are presented as a percentage of the moles of unsaturated disaccharides produced by
chondroitinase ABC digestion of the ion-exchange fractions (F1–F6).
CS/DS Disaccharides F1 (%) F2 (%) F3 (%) F4 (%) F5 (%) F6 (%)
∆HexA-GalNAc 70.6 72.4 86.4 8.8 3.5 3.6
∆HexA-GalNAc(4S) 23.1 26.7 13.6 89.9 56.8 35.0
∆HexA-GalNAc(6S) 3.8 0.2 0.0 1.4 3.7 4.3
∆HexA(2S)-GalNAc(4S) 0.0 0.0 0.0 0.0 0.0 0.0
∆HexA(2S)-GalNAc(6S) 0.0 0.0 0.0 0.0 1.8 3.9
∆HexA-GalNAc(4S)(6S) 2.5 0.8 0.0 0.0 34.2 53.2
∆HexA(2S)-GalNAc(4S)(6S) 0.0 0.0 0.0 0.0 0.0 0.0
Unsulfated 70.6 72.4 86.4 8.8 3.5 3.6
2-O-SO3 0.0 0.0 0.0 0.0 1.8 3.9
4-O-SO3 25.6 27.5 13.6 89.9 91.0 88.2
6-O-SO3 6.3 1.0 0.0 1.4 39.7 61.5
Total GAG disaccharides produced
by ABC lyase digestion (µg) 0.002 0.006 0.006 0.026 0.285 0.086
Average sulfate per disaccharide 0.32 0.28 0.14 0.91 1.31 1.51
Abbreviations: ∆HexA, 4,5 unsaturated uronic acid; GalNAc, N-acetylgalactosamine; 2S, 2-O-sulphate; 4S,
4-O-sulphate; 6S, 6-O-sulphate
Taken together, the data imply that the majority of heparinases and chondrotinase ABC susceptible
linkages, and therefore GAG-like structures, are present in the later eluting fractions from the
ion-exchange separation. The production of a significant quantity of HS disaccharides, from the
highly active Fraction 5, confirms the link between HS-GAG-like structures and the antiproliferative
activity of the cockle polysaccharides. However, the residual activity of the heparinase resistant chains
must also be taken into account when judging any structure/activity relationships.
2.9. Monosaccharide Analysis of Ion-Exchange Purified Polysaccharides
The lack of information regarding the identity of the uronic acid moieties, using the method of
disaccharide analysis employed in this study, means that we cannot identity potentially important
structural features within the GAG-like chains. We are also missing structural detail on the content of
non-GAG-like components of the cockle polysaccharide preparations. These issues can be clarified by
total acid hydrolysis and monosaccharide analysis of both the unfractionated cockle polysaccharides
and the ion-exchanged purified fractions. Analysis of the unfractionated cockle polysaccharide
preparations (Table 4) showed the presence of significant quantities of the monosaccharides, GalNH2,
GlcNH2, and GlcA, which are typically found following acid hydrolysis of mammalian and marine
GAG chains. Interestingly, there was no detectable IdoA component. Fucose made up about
10% of the monosaccharides produced and could be derived from fucoidan-like or fucosylated CS
glycans. The neutral sugars glucose (Glc) and galactose (Gal) were by far the most predominant
monosaccharaides present in the unfractionated cockle polysaccharide preparations and represent
components typically found in marine N- and O-linked glycans. Mannose represented less than 4%
of the monosaccharides released by hydrolysis, and was predominantly found in Fractions 2 and
6. The data support the presence of GAG-like chains, as was indicated by both the susceptibility of
cockle polysaccharides to heparinase/chondroitinase ABC digestion, and the production of a range
of unsaturated disaccharides, typically found in mammalian GAG chains. Analysis of ion-exchange
purified fractions showed enrichment of the GAG related monosaccharides GalNH2, GlcNH2, and GlcA
in the later eluting fractions (Fractions 3–6) and critically the antiproliferative Fraction 5, which also
contained the highest amount of GlcA.
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Table 4. HPAEC-PAD analysis of monosaccharides derived from unfractionated (crude) cockle
polysaccharide and ion-exchange purified fractions (F1–F6). Samples (50 µg) were degraded to
monosaccharides by treatment with TFA prior to high performance anion exchange chromatography
with pulsed amperometric detection (HPAEC-PAD) analysis. The peaks observed were identified
by comparison to the elution position of known monosaccharide standards. Data are presented as a
percentage of the moles of monosaccharide produced by acid hydrolysis.
Monosaccharide Crude (%) F1 (%) F2 (%) F3 (%) F4 (%) F5 (%) F6 (%)
Fuc 11.1 5.1 5.8 3.3 3.6 14.2 2.1
GalNH2 16.7 3 4.0 11.7 35.6 21.8 9.5
GlcNH2 9.9 3.9 2.1 11.9 10.4 14.5 3.6
Gal 19.1 2.3 3.0 11.0 14.4 20.1 8.8
Glc 35.2 73.5 57.4 52.9 30.0 10.4 50.4
Man 3.7 5.0 28.1 7.4 2.7 4.9 23.5
GlcA 4.3 1.0 0.7 1.9 3.3 14.1 2.1
IdoA 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Abbreviations: Fuc, fucose; GalNH2, galactosamine; GlcNH2, glucosamine; Gal, galactose; Glc, glucose; Man,
mannose; GlcA, glucuronic acid; IdoA, iduronic acid :
Overall, the data indicate the presence of a diverse range of glycan chains, including GAG-like
structures, within the unfractionated cockle polysaccharide preparations. The components found in
the active Fraction 5 are clearly GAG-like in nature. The lack of IdoA is an interesting observation,
yet this does not, on its own, explain the unique activity of the cockle derived HS-like GAG chains.
The complexity of the cockle polysaccharide preparations, even within the ion-exchange purified
fractions, and the limitations of the compositional analysis tools used in this study make it difficult to
determine the exact structural differences between the antiproliferative cockle HS-like GAG chains and
their inactive mammalian counterparts. We also need to consider the nature of the antiproliferative
activity that remains following extensive heparinase digestion.
3. Discussion
We have shown for the first time that marine derived polysaccharides, with proven anticancer
activity, are susceptible to the effects of heparinase digestion. The results, in conjunction with the
lack of antiproliferative activity of mammalian GAGs, suggest that atypical GAG structures are
present in marine polysaccharides from mollusc sources. These unique structures can be directly
linked, at least in part, to the antiproliferative activity seen on human cancer cell lines treated with
cockle polysaccharides.
Anti-metastatic and antiproliferative activity of marine derived polysaccharides has previously
been observed from a variety of sources, such as algae, ascidians, euechinoidea, molluscs and
bacteria [20]. The active molecules identified to date are classes of sulphated polysaccharides,
such as sulphated fucans and sulphated galactans, which are defined as non-GAG glycans.
They differ from typical mammalian GAG family members in several ways, including their relative
homogeneity, in terms of their monosaccharide compositions and distribution. Their most dramatic
structural differences lie in the type of monosaccharide building blocks that make up these chains.
Sulphated fucans are polymers of fucopyranso units, which may contain variable amounts of neutral
monosaccharides and uronic acids and are predominantly classed as fucoidans [9,21], whereas
sulphated galactans are almost exclusively composed of Gal units [22]. None of the glycosidic linkages
within these marine polysaccharides has any reported susceptibility to the enzymes used in this study.
Hence, the reduction in antiproliferative activity we observed following heparinase digestion of the
cockle polysaccharides suggests that the anticancer activity of the intact chains is linked to the presence
of archetypal mammalian GAG disaccharide structures. Clearly, this is divergent with the literature
that to date has exclusively linked anticancer activity of marine polysaccharides to non-GAG glycans.
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Some heterogeneity has been reported for some of the sulphated fucans [23], and galactans [24].
However, none of the variations was connected to the presence of mammalian like GAG disaccharides.
We have not yet considered previously discovered marine polysaccharides that are closely
related to traditional mammalian GAG structures, such as fucosylated CS, dermatan sulphate-like
polysaccharides, GlcA containing HS and highly sulphated hybrid heparin/HS chains. Despite their
widespread presence, no antiproliferative activity, on cancer cell lines, has previously been attributed
to these polysaccharides classes. Fucosylated CS from holothuroidea has been reported to be insensitive
to chondroitinase ABC digestion, without prior removal of fucose residues [25] and highly sulphated
dermatan-like polysaccharides from tunicates have been shown to be sensitive to chondroitinase
ABC digestion [26,27]. In our study, unsaturated disaccharides were produced by chondroitinase
ABC digestion of cockle polysaccharides, although this had no effect on the antiproliferative
activity. We have not confirmed the presence of fucosylated CS or dermatan like polysaccharides
in the active cockle polysaccharide fractions. As such, we cannot rule out a contribution by these
types of structure to the observed antiproliferative effects. However, the absence of IdoA in the
monosaccharide analysis suggest that dermatan-like structures are unlikely to be present in the cockle
polysaccharide preparations.
The heparin/HS type of polysaccharide chains identified from marine sources include a report
of a unique hybrid heparin/HS polysaccharide found in the head of shrimp. These marine
heparin/HS hybrid GAGs were extensively degraded by heparinase enzymes [28]. The GlcA
containing HS-like GAGs derived from the mollusc Nodipecten nodosus represents another heparinase
sensitive structure that may be linked to the antiproliferative activity of the cockle polysaccharides [29].
Although no antiproliferative activity has been reported, to date, with either of these types of
glycan chains, the cockle polysaccharides did loose significant antiproliferative activity, following
heparinase degradation (Figure 3). This observation might be linked to the presence of similar
hybrid heparin/HS or GlcA-rich HS structures in the cockle polysaccharide preparations. However,
appreciable antiproliferative activity did remain, even after extensive heparinase treatment of the
unfractionated cockle polysaccharides. Suggesting that other atypical GAG structures are potentially
involved in the antiproliferative activity. A reductionist assessment of the structural features within
these heparinase resistant sequences represents an attractive approach that may well lead to a more
thorough understanding of precise structural features required to facilitate that anticancer activity
seen in this study.
Disaccharide analysis was employed to identify compositional differences between the building
blocks of known marine/mammalian GAGs and the antiproliferative chains within cockle-derived
polysaccharides. Our data showed that heparinase I, II, III treatment of cockle polysaccharides liberated
all of the most abundant unsaturated disaccharide types typically observed in mammalian GAGs.
The rare 3-O-sulphated disaccharides were not detected in any of the cockle polysaccharide samples,
using the methods described here. The most significant feature of the analysis appeared to be related
to the overall levels of N-sulphated disaccharides produced by heparinase digestion, which accounted
for approximately two thirds of the disaccharide units obtained from the unfractionated cockle
polysaccharide preparations. The antiproliferative ion-exchange purified, Fraction 5, yielded in
access of 80% N-sulphated disaccharides, as opposed to the much lower levels, typically around
50%, produced by combined heparinase digestion of mammalian HS. For example, porcine mucosal
HS contains approximately 40% N-sulphated disaccharides [30]. Mammalian heparins typically
have higher N-sulphate levels, averaging around 85% of the disaccharide units [31]. The other
notable differences are in the levels of the disaccharides ∆HexA(2S)-GlcNS and ∆HexA-GlcNS(6S)
generated by combined heparinase digestion of some of the ion-exchange purified fractions, making up
24.4% and 19.4% of the disaccharides liberated from the active Fraction 5, respectively, as opposed
to the percentage of these disaccharide in porcine mucosal heparin (0.9% and 14.6%, respectively),
porcine mucosal HS (10.4% and 3.9%, respectively), bovine kidney (2.9% and 5.1%, respectively) and rat
liver HS (14.5% and 6.2%, respectively) [30,31]. Despite Fraction 5 showing significant antiproliferative
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activity in comparison to the inactive porcine mucosal HS, it seems unlikely that the increased presence
of these disaccharides is solely responsible for the differences in antiproliferative activity observed
in this study. In fact, the analysis of the disaccharides liberated from the unfractionated cockle
polysaccharides, and the active Fraction 5, by heparinase gave no definitive clues to the differences in
biological activity seen between the marine sourced cockle polysaccharides and mammalian GAGs.
Overall, the lack of antiproliferative activity of mammalian GAGs suggest that a radically different
type of HS-like structure may be present in the cockle polysaccharides.
Analysis of the monosaccharide composition of the cockle polysaccharides, again failed to give
a conclusive insight into the specific glycan structures that might be facilitating the antiproliferative
activity of these glycan chains. The monosaccharide analysis did confirm that GAG-like structures
where enriched in the unfractionated cockle polysaccharides and the active Fraction 5. However,
this compositional detail and the complete absence of IdoA in the cockle polysaccharides does not yet
represent sufficient evidence to conclude the exact nature of the antiproliferative glycan structures.
It might be suggested that the antiproliferative effects observed in this study, simply represent
a non-specific structure/activity relationship linked to the very high sulphate content of the cockle
polysaccharides and the active Fraction 5. To the authors knowledge no studies have demonstrated
any direct antiproliferative effects of mammalian heparins on cancer cells, using in vitro MTT assays,
despite their high sulphation levels. A report has been published, in which a clinical preparation of low
molecular weight heparin showed slight inhibition of a human lung adenocarcinoma A549 cell line by
MTT assay. However, 50% inhibition was never achieved at the concentrations used [32]. In addition,
the low molecular weight heparins used failed to induce apoptosis, unlike the cockle polysaccharides
(Figure 2). Intact high molecular weight porcine mucosal heparins, used in our study, failed to show
any inhibition of cancer cell growth (results not shown). In addition, the activity profile for the
ion-exchange purified fractions showed that the more heavily sulphated Fraction 6 had significantly
less antiproliferative activity than the earlier eluting Fraction 5. However, both fractions produced
HS/heparin like disaccharides following heparinase treatment and Fraction 6 had a higher overall
sulphate content (Table 2). Taken together, these results suggest that the high levels of sulphation
found in these cockle polysaccharides are not the principle reason for their antiproliferative activity.
Hence, it is likely that specific sequences within the polysaccharides are mediating their biological
activities in a distinct manner.
Marine polysaccharides continue to attract great interest as molecules with the potential for
therapeutic development. In this study, we have identified antiproliferative and apoptotic activity
in sulphated polysaccharides isolated from a marine mollusc. These novel GAG-like chains differ
significantly from their mammalian counterparts, in terms of structure and anticancer activity, and have
the potential to be developed into new a new class of cancer therapeutics.
4. Materials and Methods
4.1. Extraction of Sulphated Polysaccharides
Polysaccharides were extracted from common cockle (Cerastoderma edule), obtained from the Irish
Sea, British Isles, using a standard protocol [19]. Shells were removed and the entire soft body tissue
was defatted by incubation with acetone for 72 h. Defatted tissue was left to dry for 24–48 h then
ground to a fine powder. The powder (4 g) was suspended in 40 mL of 0.05 M of sodium carbonate
pH 9.2, and 2 mL of Alcalase enzyme (Merck, Millipore, Watford, UK) added. Samples were then
incubated at 60 ◦C for 48 h with constant agitation at 200 rpm. The mixture was then cooled at 4 ◦C and
trichloroacetic acid (Sigma-Aldrich, Gillingham, UK) added to a concentration of 5% (w/v) and left for
10 min. Precipitated peptides were removed by centrifugation (5000× g for 10 min). The supernatant
was retained and three volumes of 5% (w/v) potassium acetate in ethanol was added to one volume of
supernatant and the mixed solution left overnight at 4 ◦C. Precipitated cockle polysaccharide chains
were recovered by centrifugation (5000× g for 30 min) and the pellet washed with absolute alcohol.
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The recovered precipitate (1 g) was then dissolved in 40 mL of 0.2 M NaCl solution and centrifuged
(5000× g for 30 min) to remove any insoluble material. Cetylpyridinium chloride (Sigma-Aldrich)
(0.5 mL of a 5% (w/v) solution) was added to the supernatant and the precipitate formed, recovered by
centrifugation (8000× g for 30 min). The precipitate was subsequently dissolved in 10 mL of 2.5 M NaCl
solution, followed by the addition of 5 volumes of ethanol. The precipitated cockle polysaccharide
chains were recovered by centrifugation (8000× g for 30 min) before being dialysed against water for
72 h. The dialysate was lyophilized to obtain a white powder containing approximately 2.0 mg of
cockle polysaccharides.
4.2. Maintenance of Cell Lines
Human cancer cell lines K562 (Chronic myelogenous leukaemia) and MOLT-4 (acute T
lymphoblastic leukaemia) were grown in RPMI-1640 medium containing 1 g/L glucose (Lonza Group
Ltd., Basel, Switzerland), supplemented with 10% (v/v) inactivated FBS (Labtech International
Ltd., Heathfield, UK), 2 mM L-glutamine (Labtech International Ltd.), 100 Units/mL penicillin and
100 ug/mL streptomycin (Labtech International Ltd.). All cell lines were maintained in 25 cm2 flasks
under a humidified atmosphere of 95% air and 5% CO2 at 37 ◦C.
4.3. Cell Viability Assay
Cell viability was assessed using an MTT (3-(4,5 dimethylthiazol2-yl)-2,5 diphenyltetrazolium
bromide) (Sigma-Aldrich) assay. Cells were seeded at a density of 5 × 104 cells/well and cultured
overnight in 96-well plates containing 100 µL of culture medium prior to treatment with polysaccharide
samples. Treatment was conducted for 96 h following addition of various concentrations of cockle
polysaccharides and mammalian GAGs (Celsus, Cincinnati, OH, USA) (0–50 µg/mL), with cisplatin
(0–25 mM) as a positive control. At the end of the incubation period, 50 µL MTT solution (5 mg/mL
in PBS) was added to each well and incubated for 3 h at 37 ◦C. Next, 200 µL of DMSO was added to
each well and the plates agitated to dissolve the formamazan crystal product. The amount of MTT
converted to formazan is indicative of the number of viable cells. The plates were gently agitated
until the colour reaction was uniform and the absorbance was measured at 570 nm using a multi-well
plate reader. The cell viability effects from exposure of cells to each concentration of crude cockle
polysaccharides, commercial mammalian GAGs and cisplatinum (Sigma-Aldrich) were analysed as
percentages of the untreated control cell absorbance. The average cell survival obtained from triplicate
determinations, at each concentration, was plotted as a dose–response curve. The IC50 values were
calculated using nonlinear regression analysis (GraphPad Prism 5.0, La Jolla, CA, USA)
4.4. Cell Cycle and Annexin V Apoptosis Assay
Cells were seeded into sterile 6-well plates at 5 × 105/mL, and incubated with or without
cockle polysaccharides at 37 ◦C. Cells were harvested at designated time intervals, centrifuged at
2000× g for 5 min, washed twice with cold PBS and resuspended in 1 × binding buffer (0.1 M HEPES
(Sigma-Aldrich), 1.4 M NaCl and 25 mM CaCl2) at a concentration of 1 × 106 cells/mL. Cells (100 µL)
were then transferred into 5 mL culture tube and stained with Annexin V-FITC (5 µL) and propidium
iodide (PI) (Sigma-Aldrich) (10 µL). The stained cells were gently vortex for few seconds and incubated
in the dark for 15 min at room temperature. Binding buffer (400 µL) was added to each tube prior
analysis by flow cytometer (BD FACSVerse, Franklin Lakes, NJ, USA). Prior to flow cytometry cell
cycle analysis, cells (100 µL) were centrifuged, washed in PBS three times and incubated at room
temperature with 50 µL of Ribonuclease A (RNase) (50 mg/mL) before staining with a solution
containing 50 µg/mL propidium iodide (PI) for 30 min in the dark.
4.5. Enzymatic Digestion
Polysaccharide samples were digested by heparinase or chondroitinase ABC prior to MTT
assay, as follows. Enzyme buffer comprised of 10 mM calcium acetate and 50 mM sodium acetate
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pH 7.0 containing 30 mIU of heparinase I, II, III (Grampian Enzymes, Aberdeen, UK) separately
or in combination was added to solutions of 100 µg of cockle polysaccharides in enzyme buffer.
Chondroitinase ABC (Grampian Enzymes, Aberdeen, UK) (30 mIU) in enzyme buffer was added to
100 µg cockle polysaccharides and incubated for 24 h at 37 ◦C. The enzyme digests were monitored
spectrophotometrically at 232 nM and the reactions terminated by heating at 100 ◦C for 5 min.
4.6. Ion-Exchange Chromatography
Crude cockle polysaccharide preparations were fractionated by anion exchange chromatography,
using an FPLC system (Pharmacia, Stockholm, Sweden). Samples were applied to an ion-exchange
column (16 × 200 mm), packed with 10 mL of DEAE-Sepharose (GE Healthcare, Little shallot, UK).
Cockle polysaccharides were eluted using a linear 0–1.5 M NaCl gradient in 50 mM sodium phosphate
buffer pH 7.0 over 70 min at a flow rate of 1 mL/min. Absorbance was monitored at 280 nm, 1 mL
fractions were collected. and pooled as indicated.
Pooled fractions, corresponding to the peaks in the elution profile were dialysed extensively
against water using 14 kDa molecular weight cut-off tubing (Scientific Laboratory Supplies,
Nottingham, UK). After dialysis, peaks were lyophilised, and stored at −20 ◦C.
4.7. HPAEC-PAD Monosaccharide Analysis
HPAEC-PAD was preformed to determine monosaccharide composition, using a Dionex ICS-3000
system (Sunnyvale, CA, USA) [33]. Crude cockle polysaccharides (50 µg) or pooled peaks from the
ion-exchange chromatography separation, were dissolved in 200 µL of MilliQ water. The mixture was
then hydrolysed using 1 mL of trifluoroacetic acid at 100 ◦C for 6 h to ensure complete hydrolysis of
polysaccharides to monosaccharides. Monosaccharide samples were next centrifuged at 2000 rpm for
2 min. Acid was removed using a dry nitrogen flush after addition of 50 µL of 50% (v/v) aqueous
isopropyl alcohol. Monosaccharide samples (20 µg) were applied to a Dionex CarboPac PA1 column,
4 mm× 250 mm, using a 4 µm and 4 mm× 50 guard column at a flow rate 1 mL/min. Monosaccharides
were eluted using a gradient formed from three solvents: water as solvent A, 100 mM NaOH with
5 mM NaOAc as solvent B, and 100 mM NaOH with 250 mM NaOAc as solvent C. Peaks were detected
using pulsed amperometric detector with standard quad waveform.
4.8. Disaccharide Analysis
The cockle polysaccharide samples were fractionated by ion-exchange chromatography prior to
disaccharide analysis as described previously.
Crude cockle polysaccharide or ion-exchange fractionated polysaccharides were incubated with a
mixture of 10 mIU each of heparinases I, II, and III in lyase buffer (100 mM sodium acetate pH 7.0,
containing 0.1 mM calcium acetate). Samples were incubated overnight at 37 ◦C and the reaction
terminated by heating to 100 ◦C for 5 min. The samples were passed through a 10 K MWCO spin
filter then dried before further analysis. GC-MS and isotopic aniline tagging (GRIL-Glycan Reductive
Isotope Labelling) was used for composition analysis and mass detection of disaccharide yield from
heparinase treated cockle polysaccharides [34]. 15 µL of 12C6 labelled Aniline and 15 µL of 1 M sodium
cyanoborohydride, freshly prepared in DMSO:acetic acid (7:3, v/v), was added to 8 ρmol of dried
heparinase derived disaccharides. Reactions were carried out at 37 ◦C for 16 h, and then dried in a
centrifugal evaporator. The dried samples were prepared for LCQ-MS analysis by resuspending in
running buffer (8 mM acetic acid, 5 mM dibutylamine (DBA)) followed by centrifugation at 14,000× g
for 7 min. The supernatant (5 µL) was spiked with an 8 ρmol solution of unsaturated disaccharide
standards tagged with13C6 aniline (2 µL) and the sample made up to 10 µL with running buffer.
Aniline isotopic and non-isotopic disaccharides were separated on a C18 reversed-phase column
(0.46 cm × 25 cm, Vydac). The solvent system used to elute the samples was 100% buffer A (8 mM
acetic acid, 5 mM DBA) for 10 min, 17% buffer B (70%, methanol 8 mM acetic acid 5 mM DBA) for
15 min, 32% buffer B for 15 min, 40% buffer B for 15 min, 60% buffer B for 15 min, 100% buffer B
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for 10 min and 100% buffer A. Ions of interest were detected in negative ion mode and the capillary
temperature and spray voltage were kept at 140 ◦C and 4.75 kV, UV detection was at 232 nm.
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